Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Literature DB >> 28042310

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Holger Gerullis¹, Friedhelm Wawroschek², Claus-Henning Köhne³, Thorsten Holger Ecke⁴.

Abstract

Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.

Entities: Chemical Disease

Keywords: mTCCU; metastatic urothelial carcinoma; second line; urothelial cancer; vinflunine

Year: 2016 PMID： 28042310 PMCID： PMC5167074 DOI： 10.1177/1756287216677903

Source DB: PubMed Journal: Ther Adv Urol ISSN： 1756-2872

37 in total

1. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

Authors: Andrea Necchi; Luigi Mariani; Nadia Zaffaroni; Lawrence H Schwartz; Patrizia Giannatempo; Flavio Crippa; Carlo Morosi; Rodolfo Lanocita; Teodoro Sava; Cinzia Ortega; Caterina Messina; Cosimo Sacco; Marzia Pennati; Maria G Daidone; Nicola Nicolai; Filippo De Braud; Alessandro M Gianni; Roberto Salvioni
Journal: Lancet Oncol Date: 2012-07-20 Impact factor: 41.316

Review 2. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.

Authors: A Kruczynski; B T Hill
Journal: Crit Rev Oncol Hematol Date: 2001-11 Impact factor: 6.312

3. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes.

Authors: Xiao-Ping Zhao; Jiao Zhong; Xiao-Quan Liu; Guang-Ji Wang
Journal: Acta Pharmacol Sin Date: 2007-01 Impact factor: 6.150

4. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.

Authors: A Kruczynski; J M Barret; C Etiévant; F Colpaert; J Fahy; B T Hill
Journal: Biochem Pharmacol Date: 1998-03-01 Impact factor: 5.858

5. Real-World Vinflunine Outcomes in Bladder Cancer in a Single-Institution Study: Moving Beyond Clinical Trials.

Authors: Guillaume Moriceau; Alexis Vallard; Romain Rivoirard; Benoîte Méry; Sophie Espenel; Julien Langrand-Escure; Majed Ben Mrad; Guoping Wang; Peng Diao; Cécile Pacaut; Aline Guillot; Olivier Collard; Pierre Fournel; Nicolas Magné
Journal: Clin Genitourin Cancer Date: 2015-06-06 Impact factor: 2.872

6. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium.

Authors: John D Hainsworth; Anthony A Meluch; Cassie M Lane; David R Spigel; Howard A Burris; Jitendra G Gandhi; Edward J Crane; Michael A Stipanov; F Anthony Greco
Journal: Cancer Invest Date: 2010-03 Impact factor: 2.176

7. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway.

Authors: Bertrand Pourroy; Manon Carré; Stéphane Honoré; Véronique Bourgarel-Rey; Anna Kruczynski; Claudette Briand; Diane Braguer
Journal: Mol Pharmacol Date: 2004-09 Impact factor: 4.436

8. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.

Authors: Peter Johnson; Thomas Geldart; Pierre Fumoleau; Marie-Claire Pinel; Laurent Nguyen; Ian Judson
Journal: Invest New Drugs Date: 2006-05 Impact factor: 3.651

9. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.

Authors: S Culine; C Theodore; M De Santis; B Bui; T Demkow; J Lorenz; F Rolland; F-M Delgado; B Longerey; N James
Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640

10. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.

Authors: Nikolaos Pistamaltzian; Kimon Tzannis; Vassiliki Pissanidou; Stavros Peroukidis; Georgia Milaki; Vasilis Karavasilis; Iraklis Mitsogiannis; Ioannis Varkarakis; Athanasios Papatsoris; Athanasios Dellis; Ioannis Adamakis; Konstantinos Stravodimos; Dimitra Molyva; Ilias Athanasiadis; Nikos Androulakis; Charalambos Andreadis; Charalambos Kalofonos; Dionisios Mitropoulos; Charalambos Deliveliotis; Constantinos Constantinides; Meletios A Dimopoulos; Aristotelis Bamias
Journal: Anticancer Drugs Date: 2016-01 Impact factor: 2.248

9 in total

Review 1. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.

Authors: Deepali Waghray; Qinghai Zhang
Journal: J Med Chem Date: 2017-12-28 Impact factor: 7.446

2. Solventless and Metal-free Regioselective Hydrofluorination of Functionalized Alkynes and Allenes: An Efficient Protocol for the Synthesis of gem-Difluorides.

Authors: Zhichao Lu; Bhvandip S Bajwa; Shiwen Liu; Sheye Lee; Gerald B Hammond; Bo Xu
Journal: Green Chem Date: 2019-02-15 Impact factor: 10.182

Review 3. Addressing artifacts of colorimetric anticancer assays for plant-based drug development.

Authors: Salma Batool; Seejal Javaid; Hira Javed; Izzah Shahid; Mishal Khan; Amna Muhammad
Journal: Med Oncol Date: 2022-09-07 Impact factor: 3.738

Review 4. Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.

Authors: Joanna Kałafut; Arkadiusz Czerwonka; Alinda Anameriç; Alicja Przybyszewska-Podstawka; Julia O Misiorek; Adolfo Rivero-Müller; Matthias Nees
Journal: Cancers (Basel) Date: 2021-12-10 Impact factor: 6.639